Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
GlobeNewswire
· Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results;..
